Board of Directors

Our Board of Directors is a group of leadership volunteers who together set the strategic direction for our work and ensure we are operating with integrity and accountability.

Barbara M. Hill, Chair
Robert Deane, Vice Chair
Vincent Hamel
John Bennett
Karen Corraini
Kathryn Deuchars
Marie-Pier Emery

Chelsea Jalloh
François Levert
Aleka MacLellan
Stephen McCourt
Stephanie Nerlich
Robert Sankey
Tim Trussell

*Andre, who lives with CF, and sibling Eleanor
*On the cover: The Bennett family (top image); a visit to the CF clinic (middle photo); Rianna, who lives with CF (bottom photo)*
For those who know the reality of cystic fibrosis, there is community to be found in shared experience and in working together to make change. But we now find ourselves at a crossroads with life-changing treatments available for many. This is something to celebrate – and also a chance to recommit to the need that still exists. Too many people with CF are dying far too young. The disease continues to limit people’s daily lives. And one in seven Canadians with CF cannot access life-changing treatments.

Standing still is not an option. Which is why throughout 2023/24, we focused on moving forward as a community – together, making meaningful strides towards a future where all Canadians with cystic fibrosis can live longer, healthier, better lives.

Whether you are a donor, volunteer, advocate or ambassador, your support fueled continued progress in 2023/24, including:

- Successfully advocating for access to Trikafta for children aged two to five, with five public drug programs covering the treatment by year end;
- Introducing guidelines that support clinicians in delivering consistent and high-quality care;
- Creating a nationwide inventory of mental health supports that will help empower people with CF to improve their emotional wellbeing; and
- Investing nearly $3 million in research that is foundational to improving treatment and care.

We recognize the CF community is in uncharted territory. Some people are living longer than ever with CF – which also means an increase in complications like kidney disease, diabetes, osteoporosis, cancers, and cardiovascular issues that emerge as people age.

We still have much work to do to ensure healthy, full lives for everyone. That’s why we put significant effort in 2023-24 into developing a new strategic plan for our organization – a roadmap to guide our efforts that was informed by more than 600 people in the CF community and consultations with our partners here and around the world. We also looked carefully at how we deliver our work so that we ensure we continue to meet the needs of our CF community now and for the future.

Now is the time to lean into the momentum that we’ve created. That you’ve created. We must continue pushing for those who face a higher disease burden. Those who are sicker, are at greater risk of mental health issues, or have fewer supports because of where they live.

All Canadians with CF must live fully, beyond the limits of CF. We won’t stop until they do. And thanks to the passion and commitment of the CF community, we know we will get there. Together.

Thank you for your incredible support. It powers us to keep moving forward.

Barbara M. Hill
Chair

Kelly Grover
President and CEO
A new lease on life
Improving access to life-changing and life-sustaining medicines

Working with the CF community, we continue to push for access to CFTR modulators. By helping certain mutated CF proteins function better, these drugs significantly improve the health and wellbeing of many people diagnosed with CF. In 2023/24 we added to our advocacy successes with even more Canadians gaining access to these drugs – and with them, the chance for a healthier life. Thanks to a strong and engaged network of patient advocates and clinical experts, we continue to set the standard for effective advocacy recognized by government as top-notch work.
Since our son Andre has been able to access Trikafta, our preventative therapy has been reduced from 2 hours a day to around 30 minutes maximum. His salt chloride levels are within the normal range, his pancreas is fully functional and his nasal polyps have disappeared. He no longer even needs to take enzymes. He’s been lucky to not have had any respiratory symptoms and hopefully he never will.

Dave Clair, CF Parent, Toronto, ON

The difference advocacy makes

For the last several years, we’ve advocated tirelessly for all Canadians with CF to have access to Trikafta. That’s why we were thrilled in 2022 to see all public drug plans cover Trikafta for Canadians aged 6 and older with at least one F508del gene mutation. And now, we have the data to measure the difference that advocacy has made. According to the Canadian Cystic Fibrosis Registry Annual Data Report, approximately 2,500 Canadians with CF were taking CFTR modulator therapies in 2022, the most recent year for which data are available. That represents a 70% increase over the previous year and is more than five times the number of Canadians taking CFTR modulators in 2018.¹


Protecting the health of the CF community from a younger age

In October 2023, Health Canada approved Trikafta for use in a younger cohort of Canadians with at least one F508del gene mutation: those aged two and up, instead of six and up as had been approved previously. We immediately called on provinces and territories to cover the drug in this younger age group. That’s because starting young children on a modulator therapy as early as possible could protect their health and prevent significant structural lung damage from occurring. By the end of the year, four provinces and territories, along with the federal drug program for registered First Nations and recognized Inuit, had added Trikafta to their public drug plans for children aged 2-5 with the most common mutation. We continue to work hard so all children in Canada with a F508del gene mutation will have access to this life-changing drug – one of several CFTR modulator therapy options now available for many of Canada’s youngest CF patients.

What’s next?

We’ve had good reason to celebrate Trikafta’s arrival in Canada. But we also know it’s not a cure. Its long-term benefits are unknown, and it will not take away the years of damage CF has had on many people’s bodies. Others cannot yet access it in Canada because of the genetic mutation they have, or because it is not being covered through public or private drug plans. Looking ahead, we will continue to advocate for expanded access to all who can benefit from Trikafta and other CFTR modulator therapies, and we will work to address the financial burden that many Canadians still face in accessing them.
Keeping pace with change
Improving the treatment and care experience

For many Canadians, living with CF today looks very different than even five years ago. As people live longer and have more diverse needs, the CF healthcare team must be equipped with resources and evidence-based tools to deliver the highest quality of care. Similarly, people living with CF need the most up-to-date information to navigate their health journey – especially between clinic visits. Your support in 2023/24 meant we could better align information and care with the current state of CF, so the community can benefit from the best available support and expertise.
The best available care, no matter when or where

Cystic fibrosis is changing, and the clinical guidance followed by healthcare professionals needs to align with the newest information. Through our Healthcare Advisory Council (HAC), we are creating new clinical guidelines and standards of care informed by the latest research and clinical trials, so that CF patients can receive the best possible care. In 2023/24, we introduced clinical care guidelines for pulmonary exacerbations and recommendations for monitoring the health of babies whose mothers are taking CFTR modulators. We have begun work on health human resources guidelines that will recommend staffing models to support all 40 CF clinics in advocating to provide optimal care. We also supported Canadian CF clinicians to learn from one another through knowledge exchange sessions and various clinician meetings on hot topics including rare mutations and airway clearance in an era of CFTR modulator therapies.

Easing CF’s heavy emotional burden

People with CF and their caregivers are two to three times more likely to suffer from anxiety and depression, and the Canadian CF community has identified mental health supports as a top priority. That’s why the right resources are such an important part of our information and support offering. In 2023/24, we worked with our Adult Cystic Fibrosis Advisory Committee on issues they identified as important including fertility and hospital hacks. We also hosted a mental health webinar for the community, introduced a resource to help clinicians have conversations with their patients about Trikafta and mental health impacts, and developed a national and provincial inventory of community-based supports that will be added to our website this year.

Managing daily life between clinic visits

Our resources are one way we support the CF community to manage daily life with CF and not feel so alone, especially between clinic visits. In 2023/24, we worked with the Canadian CF dietitian group on information to help people with CF manage their nutrition while taking CFTR modulators. As we continue to develop resources that are important to the CF community, we are also working with CF clinics to identify useful resources and share them broadly with the community: for example, Cystic Fibrosis Care BC’s resource for parents of babies who have received a positive newborn screening result.
I have experienced dark times since my son’s diagnosis. While the staff at CF clinics have offered lots of personal support, resources are limited and the services available are primarily structured to support our son. There need to be resources for the parents and loved ones that are sharing the burden of this disease.

James Fournier, CF Parent of Leroy (pictured), Montreal, QC

What’s next?

The CF community is becoming more diverse: some people will live longer than we could have previously imagined with longer-term impacts that are still unknown, while others are still very sick and cannot benefit from new treatments. Hospitalizations, lung infections, and IV antibiotics are still too common, and it’s too early to fully understand the long-term impacts of CFTR modulator therapies. We also know that needs differ across the country.

As we continue to work with the CF clinical community to improve knowledge and practice today, we are planning for the care models of tomorrow including those that respond to an aging CF population. We are prioritizing the development of national CF standards of care, finding ways to improve connection and support for people with CF and their loved ones, and working to better understand and reduce the burdens of CF care, including emotional and financial impacts. Our CF Registry will continue to play an invaluable role in understanding how CF research and care are translating into better outcomes for the community.
Research is foundational to our work because it holds great promise to change how people experience CF. We’ve already seen tremendous progress, and we want to maintain that momentum to reduce the immense health burden of CF and find treatments that work for all. Because of you, we’ve been able to invest in research aligned with the CF community’s priority needs, create new opportunities for impactful research collaborations, secure partnerships to help donor dollars go further, and commit to clinical trials as a way for Canadians with CF to access treatments in development and help researchers to understand their effectiveness.
A roadmap for continued progress and innovation

In 2023/24 we turned our vision for research investment into reality with the launch of Momentum, our roadmap for thoughtful and impactful investment in research over the next five years. In addition to funding research aligned with 11 priority areas identified by the Canadian CF community, our approach will focus on attracting the scientific minds to fuel innovation, investing in areas of unmet need, and creating impact sooner rather than later to unlock the next wave of improvements for the CF community.

Supporting continued research discovery

In 2023/24, we invested nearly $3 million in new research initiatives aligned with our Momentum research strategy to improve health outcomes for people living with CF. From studying the complexities of ageing with CF to improving treatments for lung infections, all projects focused on addressing the health priorities of the CF community. This work was funded after careful review and evaluation by a panel of scientific experts and people with lived experience – another way we ensure our work is guided by the CF community. Partnerships with the Canadian Institutes of Health Research, Cystic Fibrosis Trust, Research Nova Scotia and Saskatchewan Health Research Foundation, who collectively contributed $700,000, helped our donors’ dollars to go even further.

Improving airway infection detection and prevention

Imagine how much faster we could solve some of CF’s biggest challenges if we were to focus more resources on tackling them. That’s the goal of a new $2 million team grant we have created to find new, non-invasive ways to improve the early detection of airway infections so that treatment can begin sooner. In 2023/24 we laid the groundwork for this investment by bringing Canada’s CF research community together to identify research questions that could be pursued through a collaborative effort designed to have near-term impact. We look forward to funding one successful collaborative team in the next year.
Until we find a modulator or other treatment options that will work for everyone, we need to continue research to treat those struggling with this disease every day. We need more options to treat lung infections. We also need to continue research on taking care of an aging CF population and the complications that come with age that we previously didn’t have to deal with. Most importantly, we can’t leave people behind.

Teresa Weger, living with CF, Weyburn, SK

Improving access to clinical trials

Clinical trials play an essential role in identifying new treatments and clinical practices that improve the lives of people living with CF. That’s why our research program includes support for CF CanACT, our clinical trials network that has experienced significant growth over the past five years. The most recent CF CanACT data show that 60% of the Canadian CF population has direct access to clinical trials via our 10 network sites (and anyone can be referred, capturing all Canadians), and that more than 360 Canadian CF patients were recruited into clinical trials in 2022 alone. In addition to playing an important role in bringing new trials to Canada, CF CanACT is helping to inform the availability of new treatments: using data that are in part from our clinical trials network, Health Canada approved Trikafta for children aged 2 to 5 with the most common CF mutation.

What’s next?

This is a pivotal time in CF research. There are still so many unknowns about the disease, new questions to be answered, and a need for solutions that will bring change sooner for those who need it most. Clinical trials will continue to play a significant role through our commitment to the CF CanACT clinical trials network: we hope to see trial data contribute to the approval and expansion of access to Trikafta for all who can benefit, including those with rare mutations and even younger children, and we are eagerly anticipating upcoming trials on RNA therapies and gene therapies for rarer mutations that are not anticipated to respond to drugs like Trikafta. Our research approach prioritizes thoughtful and impactful investments in research with a continued focus on progress—bridging gaps in knowledge, treatment, and care so all with CF can have a better future.
Our community is united by shared experiences of cystic fibrosis and a shared hope for the day when people with CF can dream more freely of their future. Thanks to progress already made, we have seen how advances in cystic fibrosis require regular updates as new information emerges. We will continue to be informed by and work with our community to ensure our programs and approaches are grounded in the needs of those with personal experience. Ongoing connection with the CF community, and working together in lockstep, is what will enable us to go further, faster.
Ensuring the community guides our work

People and families affected by CF are first-hand experts in the disease. Their involvement is essential in guiding CF research, care, support, and programs so that our work is grounded in the needs and perspectives of those most affected. Since launching the Elevate program in 2021, we are proud to now have more than 230 members who were invited to participate in a range of opportunities throughout 2023/24. These included informing our mental health work, providing perspectives on gene therapy as a possible therapy for CF, sharing insights to inform a study assessing how the burden of CF has changed since the introduction of CFTR modulator therapies, and receiving a sneak peek of our new strategic plan.

Revitalizing local and virtual connections

Volunteers built Cystic Fibrosis Canada and have been essential to our success. Based on lessons in virtual connection learned during the pandemic and feedback provided by volunteers in urban and rural settings, we have been working to ensure that future opportunities with Cystic Fibrosis Canada reflect the needs and interests of our volunteers and offer more opportunities for people diagnosed with CF to participate. Throughout 2023/24 we connected with volunteers across the country for perspectives that will help to shape a revitalized volunteer program and put resourcing in place to support its success.

Informing decision-makers about the realities of CF

It’s important that the CF community help others learn about the realities of the disease – especially those who play a role in decisions related to healthcare policy and treatment access. Following the approval of Trikafta for two- to five-year-olds with the most common CF mutation, the CF community participated in a letter-writing campaign to provincial government representatives for swift coverage of the drug so as many people as possible could access it quickly and affordably. More than 1,800 of you generously participated in this effort, which has ultimately seen success with many provinces already funding Trikafta in this younger age group, as referenced on page 5.
As an Elevate member, I was thrilled when my application to be a community reviewer was accepted and I had the chance to evaluate the research proposals Cystic Fibrosis Canada received. At first, I was worried my participation wouldn’t be impactful since I didn’t have a science background – but through the process, I realized how impactful my personal experience was as a parent with a child who had been living with CF for more than 17 years. I was able to provide insights on whether the research would resonate with the community, how aligned it was to our priorities and how likely it would be to get participants to do the clinical study as it was currently designed. I found the whole experience extremely rewarding.

Lina Bhardwaj, CF Parent, Elevate member, Community Reviewer, Woodbridge, ON

Shaping the future of Cystic Fibrosis Canada

It is a new day in cystic fibrosis. While the disease is in a state of change thanks to new therapies, many people living with CF still face an immense burden. To address the needs of the CF community today and to be ready to tackle the challenges of tomorrow, we sought the input of the Canadian CF community in developing our next strategic plan – the roadmap that will guide our work over the next several years and keep us focused on the things that matter most. More than 600 of you responded to our invitation to share your thoughts with us through a community survey. The result is a plan informed by our CF community – one that will move the needle by lessening the burdens of the disease and creating a healthier future for all affected by CF.

What’s next?

Community connection will continue to be a priority as we overcome geographical barriers by bringing people together online – uniting people from coast to coast to coast. From revitalizing the volunteer experience at CF Canada to improving the emotional wellbeing of the CF community through virtual connection, we see opportunities to play a convening role that will strengthen and deepen our collective efforts. We’ll also keep the CF community informed in response to emerging needs and issues, like gene therapies and clinical trial results with implications for treatment.
Thank you!

Cystic Fibrosis Canada’s work is fueled by a community of thousands: donors, volunteers, event participants, partners, and those with lived experience.

Because you understand the limitations of cystic fibrosis, you know how important it is to remove them.

Thank you for your time, commitment, and energy.

Your support is making a difference, every single day.

Together, we are driving change, improving treatment, and transforming lives.
Recognizing our roots

Community-based fundraising

Since Cystic Fibrosis Canada was founded in 1960, community-based support has been a huge part of our story. As volunteers, event participants, and fundraisers, your work in communities across the country has been essential to our collective accomplishments: it is because of you that CF Canada is among the world’s most impactful CF charities and the reality of people living with CF has changed for the better. Thanks for your incredible efforts in the community – for giving so generously of your time, harnessing your personal and professional networks, and being tremendous ambassadors for our shared cause.

Going further for CF

Our signature event, the Walk To Make Cystic Fibrosis History, took place on Sunday, May 28, 2023 at more than 50 locations across the country. Passionate and powerful as ever, the CF community delivered on making this a memorable event generating critical funds for CF research and support. More than 3,500 people took part in this event, raising in excess of $2.7 million.
Celebrating 60 Years of Impact: A Partnership Milestone with Kin Canada

Celebrating six decades of collaboration, we honour Kin Canada, our partner since 1964. Kin members have raised in excess of $52 million for CF Canada, including more than $550,000 this past year alone.

From galas to bingos and music festivals, from dream home lotteries to golf tournaments, and through widespread participation in the Walk To Make Cystic Fibrosis History, Kin Canada has been a dedicated and generous partner. We extend our heartfelt gratitude to Kin Canada and its members for their continuous support and unwavering commitment.

Students shine in annual fall fundraiser

In September, Canadian post-secondary students united for Shinerama 2023, generating support for CF research, advocacy, and care. Through Shine Days, 60 student leaders at 21 schools kicked off the academic year by fundraising more than $100,000. Through student-led fundraising events, online fundraising, and partnerships with local businesses, Shinerama brings thousands of students together to raise CF awareness within their communities and has raised $29 million since it began 59 years ago.
Gathering on the greens

Lawn Summer Nights (LSN) is an annual lawn bowling tournament and fundraiser in support of Cystic Fibrosis Canada. Started in honour of Eva Markvoort, a Vancouver woman who died of CF a year after LSN began, the 2023 edition of LSN brought together 187 teams in nine cities. Teams gathered on the greens at either the Classic events spanning over four summer nights or the dynamic Pop-up gatherings, donning creative uniforms and competing in good fun for the cause. Together through fundraising efforts, engaging in raffles, silent auctions, and themed costumes, participants raised an impressive $321,000, contributing to a cumulative total of $4.4 million since LSN’s inception in 2009.
Giving back through gala events

Our three gala events of 2023 offered guests a memorable experience as they came together to do something positive for the CF community.

Going strong in its 23rd year, the annual 65 Roses Gala in Vancouver saw guests gather under the big top for Cirque for a Cure. With a vintage circus theme, the magical evening was full of wonder, awe, and inspiration -- with nearly $280,000 raised in the process!

It was una noche maravillosa at the 2023 Decant Gala & Fine Wine Auction – An Evening in Spain, with record-setting results. An incredible $490,000 was raised at the Toronto event, setting it up for continued success in 2024 when it celebrates its 10-year anniversary. Later in the year, at the 2023 Fusion Gala in Unionville, Ontario, guests enjoyed an evening in Paris. This soirée incroyable raised an amazing $475,000.

From the hard-working volunteers who bring these events to life to the generous guests and sponsors whose participation is such a powerful demonstration of support for the CF community, we thank you for your role in making these galas a success.

Celebrating 60 years in Kitchener-Waterloo

2023 marked a milestone for our volunteers past and present from Kitchener-Waterloo, Ontario – a community that has been active in supporting Cystic Fibrosis Canada for 60 years! With Karen Fries and Karen McCulloch serving as key points of contact, throughout 2023/24 volunteers from Kitchener-Waterloo supported the Walk To Make Cystic Fibrosis History, advocated for access to new treatments, supported Bingo events with proceeds benefiting local pediatric and adult CF clinics, provided support to local families affected by CF, organized events including golf tournaments and the Cystic Fibrosis Gala, and held events with Kin Canada.

The long history of volunteerism that is evident in Kitchener-Waterloo is mirrored in communities across the country, where caring and committed people and families offer their time and talents to advance our mission.

"Thank you so much for your support. Every single dollar raised has brought us to this point. To look back at what the prognosis for someone with CF used to be, compared to today, shows how far we have come. There are not enough words to express our gratitude, but I’m sure seeing the lives that are changed by your donation means the most."

Sheralin Spring, CF Parent, Winnipeg, MB
25 years of partnership

A simple act of kindness 25 years ago has translated into a legacy of giving for national auto body repair shop CARSTAR, whose fundraising for Cystic Fibrosis Canada now tallies into the millions of dollars. The partnership began when a franchise owner’s granddaughter, Victoria, was diagnosed with CF. Since then, CARSTAR has been a loyal supporter and donor that participates in franchise-led Shine fundraisers as well as the Walk To Make Cystic Fibrosis History.

Fundraising elements are incorporated into regional and national conferences, with the company’s 2023 Evolution Conference alone resulting in $50,000 for Cystic Fibrosis Canada. All told, CARSTAR has raised an incredible $5 million for Cystic Fibrosis Canada and the Cystic Fibrosis Foundation in the US. We’re thrilled to celebrate our silver anniversary together – with thanks to all at CARSTAR for two and a half decades of unwavering support!

“I am humbled and blown away by the incredible support from our CARSTAR Canada network in the fight to raise valuable funds for Cystic Fibrosis Canada. When the cause was brought to the network over 25 years ago from a franchise owner whose granddaughter was diagnosed with CF, our owners rallied together with a dedicated effort to raise funds to aid research, advocacy, and care for the disease. Since beginning our partnership with CF Canada, our owners and support team have continued to find dynamic ways to raise funds, make connections and ultimately, fight for CF to stand for ‘Cure Found’.

Michael Macaluso, EVP and Group President, Paint, Collision and Glass, Driven Brands

For our corporate partners, supporting Cystic Fibrosis Canada provides national opportunities to engage employees from across the country while making a difference close to home. From philanthropic donations to community-based fundraising events and volunteer opportunities, these incredible partners are an essential part of our work to create a world without cystic fibrosis. Thank you for sharing our vision to live fully, beyond the limits of cystic fibrosis, and for playing an essential role on our collective journey to fulfill it.
Enriching a corporate culture

With 24 branches and more than 1,800 employees across the country, TK Elevator (Canada) has been a fundraising partner since 2017 and has exceeded its annual fundraising goal of $100,000 every year since. For their team, supporting Cystic Fibrosis Canada is personal: employee Meaghan Addante lived with CF. To honour her inspirational advocacy, TK Elevator employees at the company's 24 branches have participated in a variety of fundraisers including bake sales, raffles, curling bonspiels, bowling events, golf tournaments and art contests. In 2022 the organization became a national sponsor of the Walk To Make Cystic Fibrosis History in Meghan's memory and to continue her mission to inspire and educate others.

Cystic Fibrosis Canada's dedication to improving the lives of those affected by cystic fibrosis is truly inspiring. Their transparency, professionalism, and unwavering mission have deeply impressed us. Our collaboration has allowed us to witness the tangible impact they have on individuals and families dealing with this challenging disease. Working with Cystic Fibrosis Canada has not only enriched our corporate culture but also empowered our employees. It has provided a sense of purpose and camaraderie, knowing that we are contributing to a cause that matters.

Jessica Carter, Senior Director, Human Resources, TK Elevator (Canada) Limited

Thank you to our corporate partners

---

Thank you to our corporate partners
Champions for change

Leadership Giving

Cystic Fibrosis Canada’s Leadership Circle is a community of dedicated philanthropists who are champions for our life-changing work. We are pleased to recognize our Leadership Circle members who are helping to change the cystic fibrosis story by contributing at the $5,000+ level in 2023-24.*

Colleen Kohse Fund
Griffin Equity Investment Group
Clint and Nancy Griffin
Steve and Bonnie Griffin
Edmonton Oilers Community Foundation
Arrell Family Foundation
Brad and Nancy Kotush
Walmart Canada
Ross and Anne Marie Drake
Ronald Black
The Voortman Family Foundation
Bayshore Foundation
Google Community Grants
Louise Redekop
The Charles H. Ivey Foundation
Sarah Gordon Sutherland Memorial Fund
JB Schultz Family Foundation
Anthony Quinn
Deborah Coles
Maplevale Fabrication Ltd
Ross Hopkins
Google
Ron and Kim Anderson
Francoys Levert
Isaac and Judy Thau
Max and Leona Pinsky
William Watson
Simon Rodgers
The Louis & Harold Price Foundation
Andrew and Marina Davies

W. Fay Versteegh Charitable Fund
Bob and Joan Lidington
Suncor Energy Foundation
Whitecap Resources Inc.
The Charles and Grace Thomson
Designated Fund at Calgary Foundation
George and Margie Waye and Family
Birth Andersen
Canada Life
Dori-Ann and George Stubos
Dr. Patrick McDonald Medical Corp
Dream Industrial REIT
Marna Disbrow
Michael and Cara Weger
Paul Barber Foundation
Richard and Charlene Klassen
The Michael and Sonja Koerner Charitable Foundation
Cenovus Employee Foundation
Manulife Financial
Robert Eberschlag and Kerri Dawson
Robert and Carolyn Sankey
Kara Robertson
Canvas Cards Trust
FYIdoctors/Visique Enhancing Life Foundation Flow Through Fund
Kimberley Camboa
Van Allen Insurance Inc.
Jason Clarke
Todd and Sharon Kelly
Leon’s Furniture Limited

Valerie Archer
Barbara M. Hill
Jake Byers
Maria and Nicodemo Larosa
Caroline Lemay
Yoursry Bissada
Brittany Ernst
Katherine Stone
Gaëtan Pichette
Libro Credit Union
Bell Canada
Canadian Appliance Recycling Enterprise (CARE)
Microsoft Canada
598758 Ontario Inc
Maurice Colman Mansworth Medicine Professional Corporation
Roland Laird
Nic Smith
Kevin and Wilma Buhler
Doris L. Bruder Charitable Fund
Melissa Moase
David and Debra Sawrey
Fondation St-Hubert
Marian Richards
Susan Dudar
Fran and Avrum Ostry
Lavish Salon Inc.
Mike Farwell
Eleanor Carpen
We have made every effort to ensure the accuracy of this list. If you have questions or corrections, or wish to join this list and play a leadership role in moving the CF community towards a brighter future, contact us at leadershipgiving@cysticfibrosis.ca.

Shared value

Sponsors

We’re so grateful for the support of organizations that support Cystic Fibrosis Canada’s signature fundraising events. In one community or many, these dedicated groups step up across the country with cash and in-kind support that enable us to maximize donor dollars for programs and initiatives that help the CF community. Thank you to our sponsors for their generosity of spirit and belief in giving back!

Ronald S. Roadburg Foundation
Team Group Management Corp.
American Iron and Metal Inc
BMO Financial Group
Home Trust Company
MCAP
Burgundy Asset Management Ltd.
Deloitte Management Services LP
Larivière et Massicotte, Pharmaciennes
Margaret McCain
RBC Dominion Securities
Nexus Investment Management Inc.
CIBC World Markets Inc
Borden Ladner Gervais LLP
Connor, Clark & Lunn Private Capital Ltd.
RBC
Clorox Company of Canada
Berkis LLP

Grant Thornton LLP
Dentons Canada LLP
Forest City Pool & Patio Inc.
KPMG - Vancouver
LIUNA - Local 183
Odlum Brown Limited
RGF Integrated Wealth Management
Trudell Medical International
WEINS Auto Group

These listings include philanthropic contributions made directly to the organization. Please note these listings are not inclusive of gifts in kind, community fundraising, or community event sponsorship. If you wish to learn more about partnering with CF Canada or recognition, please contact communityinvestment@cysticfibrosis.ca
Monthly Giving

By giving consistently throughout the year, our Breath of Life monthly donors provide crucial sustained support. We're incredibly grateful for this reliable source of funding, which in 2023/24 translated to more than $400,000 in donations that fund all aspects of our mission. We're so thankful for our monthly donors – your regular gifts are a constant beacon of hope for every Canadian living with CF.

Legacy Giving

The Summerhayes Society is a powerful group of donors helping to shape the future of CF. As legacy donors, their gifts ensure a healthier and longer future for people with cystic fibrosis. We are extremely grateful to those who have considered CF Canada in their estate plans.

You're the reason.

Generous support from donors is the reason we've been able to make such strides in understanding cystic fibrosis, helping people to live longer than ever. We're thankful for all gifts big and small – each is a powerful demonstration of your commitment to our shared cause and an investment in a brighter future for all Canadians living with cystic fibrosis. To all our donors: thank you for your generosity and for trusting in us to improve the lives of Canada's cystic fibrosis community.
**2023-24 Financial statements**

Cystic Fibrosis Canada is fully committed to transparency and accountability of financial information. We remain in a favourable financial position as we continue to strategically invest generous donor dollars into vital cystic fibrosis research and care, to ensure donations achieve the greatest impact.

### Statement of Operations
(in thousands of dollars)
Year Ended January 31, 2024

<table>
<thead>
<tr>
<th>Revenue</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community events</td>
<td>$ 7,345</td>
<td>$ 6,949</td>
</tr>
<tr>
<td>Annual giving</td>
<td>2,076</td>
<td>2,097</td>
</tr>
<tr>
<td>Leadership gifts and sponsorship</td>
<td>1,617</td>
<td>1,532</td>
</tr>
<tr>
<td>Kin Canada</td>
<td>566</td>
<td>689</td>
</tr>
<tr>
<td>Other</td>
<td>1,055</td>
<td>799</td>
</tr>
<tr>
<td>Royalties</td>
<td>44</td>
<td>274</td>
</tr>
<tr>
<td>Bequests</td>
<td>795</td>
<td>1,452</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$13,498</td>
<td>$13,792</td>
</tr>
<tr>
<td>Less direct fundraising costs</td>
<td>3,133</td>
<td>3,108</td>
</tr>
<tr>
<td><strong>Net fundraising revenue</strong></td>
<td>10,365</td>
<td>10,684</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>$ 2,935</td>
<td>$ 3,115</td>
</tr>
<tr>
<td>Healthcare</td>
<td>1,341</td>
<td>1,133</td>
</tr>
<tr>
<td>Community engagement</td>
<td>1,832</td>
<td>1,863</td>
</tr>
<tr>
<td>Advocacy</td>
<td>754</td>
<td>708</td>
</tr>
<tr>
<td>Other</td>
<td>59</td>
<td>63</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 6,921</td>
<td>$ 6,882</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration</td>
<td>2,204</td>
<td>1,566</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,442</td>
<td>1,526</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$10,567</td>
<td>$9,974</td>
</tr>
<tr>
<td><strong>Excess (deficiency) of revenue over expenses before the undernoted</strong></td>
<td>(202)</td>
<td>710</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investment Income (Loss)</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Realized gains on investments</td>
<td>$ 374</td>
<td>$ 170</td>
</tr>
<tr>
<td>Change in unrealized loss on investments</td>
<td>(2)</td>
<td>(232)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 372</td>
<td>$(62)</td>
</tr>
<tr>
<td><strong>Excess of revenue over expenses</strong></td>
<td>170</td>
<td>648</td>
</tr>
</tbody>
</table>

### Statement of Financial Position
(in thousands of dollars)
Year Ended January 31, 2024

<table>
<thead>
<tr>
<th>Assets</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and equivalents</td>
<td>$ 8,056</td>
<td>$ 8,560</td>
</tr>
<tr>
<td>Short-term investments</td>
<td>1,458</td>
<td>1,061</td>
</tr>
<tr>
<td>Receivables and other assets</td>
<td>1,296</td>
<td>720</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$10,810</td>
<td>$10,341</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>161</td>
<td>159</td>
</tr>
<tr>
<td>Long-term investments</td>
<td>4,407</td>
<td>4,258</td>
</tr>
<tr>
<td>Capital assets</td>
<td>688</td>
<td>14</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$16,066</td>
<td>$14,772</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2024</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>$ 693</td>
<td>$ 530</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>850</td>
<td>595</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$1,543</td>
<td>$1,125</td>
</tr>
<tr>
<td>Long-term liabilities</td>
<td>901</td>
<td>195</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endowment</td>
<td>$ 94</td>
<td>$ 94</td>
</tr>
<tr>
<td>Internally restricted for research and healthcare</td>
<td>2,769</td>
<td>2,366</td>
</tr>
<tr>
<td>Unrestricted</td>
<td>10,759</td>
<td>10,992</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$16,066</td>
<td>$14,772</td>
</tr>
</tbody>
</table>
### Statement of Changes in Net Assets

(in thousands of dollars)

Year ended January 31, 2024

<table>
<thead>
<tr>
<th></th>
<th>Endowment</th>
<th>Internally restricted for research and clinics</th>
<th>Unrestricted</th>
<th>2024 Total</th>
<th>2023 Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>$94</td>
<td>$2,366</td>
<td>$10,992</td>
<td>$13,452</td>
<td>$12,804</td>
</tr>
<tr>
<td>Excess of revenue over expenses</td>
<td>$–</td>
<td>$–</td>
<td>$170</td>
<td>$170</td>
<td>$648</td>
</tr>
<tr>
<td>Transfer between funds</td>
<td>$–</td>
<td>$403</td>
<td>$(403)</td>
<td>$–</td>
<td>$–</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$94</td>
<td>$2,769</td>
<td>$10,759</td>
<td>$13,622</td>
<td>$13,452</td>
</tr>
</tbody>
</table>

### Statement of Fundraising Revenue

(Net of direct fundraising costs)

- Community events: 50%
- Leadership giving: 16%
- Annual giving: 11%
- Other: 10%
- Bequests: 8%
- Kin Canada: 5%
- Royalties: <1%

*Note: Fundraising revenue excludes realized and unrealized gains/losses on investments.*

### Uses of Funds

(Excludes direct fundraising costs)

- Research: 28%
- Administration: 21%
- Community engagement: 17%
- Indirect fundraising costs: 14%
- Healthcare: 13%
- Advocacy: 7%
- Other: <1%

Complete audited financial statements are available on our website at cysticfibrosis.ca.
The power of you

Life-changing treatments for cystic fibrosis mean so much – but there are still many people who cannot access or benefit from them. That means as an organization – as a CF community – we have much work to do.

Our pioneering CF community has brought us this far, and we’re grateful for your unwavering commitment.

Your support is still so needed, to bring about change for all affected by CF.

You have told us what is important to you. You have helped to shape what our work should look like moving forward. That will be our focus.

Together, we will...

...Reduce priority burdens faced by people living with CF.

...Improve people’s health – no matter who they are or where they live – through better access to life-changing CF therapies.

...Build for the future state of CF in Canada – one that is increasingly diverse and complex.

Let’s continue the incredible progress we’ve made – together.
Your assurance of accountability and performance

Cystic Fibrosis Canada is proud to be accredited by Imagine Canada. Our use of the Standards Trustmark is recognition that our organizational practices are aligned with national charitable and non-profit sector standards in the areas of board governance, financial accountability and transparency, fundraising, staff management, and volunteer involvement.

Cette publication est aussi disponible en français.